Adial Pharmaceuticals (ADIL)
Market Price (5/19/2026): $2.01 | Market Cap: $2.8 MilSector: Health Care | Industry: Biotechnology
Adial Pharmaceuticals (ADIL)
Market Price (5/19/2026): $2.01Market Cap: $2.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -162% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -177% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.5 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -279% High stock price volatilityVol 12M is 137% Key risksADIL key risks include [1] a severe liquidity crisis threatening its ability to fund the pivotal trial for its only drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -162% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -134%, 3Y Excs Rtn is -177% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.5 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -279% |
| High stock price volatilityVol 12M is 137% |
| Key risksADIL key risks include [1] a severe liquidity crisis threatening its ability to fund the pivotal trial for its only drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Adial Pharmaceuticals (ADIL) stock has lost about 60% since 1/31/2026 because of the following key factors:
1. Reverse Stock Split Implemented to Address Nasdaq Compliance.
Adial Pharmaceuticals executed a 1-for-25 reverse stock split effective February 5, 2026, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. While intended to boost the per-share price, such actions often signal underlying financial difficulties and can contribute to investor apprehension regarding the company's long-term viability, leading to further stock depreciation.
2. Substantial Doubt Raised About Company's Ability to Continue as a Going Concern.
In its Q1 2026 financial results, Adial Pharmaceuticals disclosed a net loss of $2.0 million and reported cash and cash equivalents of $4.6 million as of March 31, 2026. The company explicitly stated that its existing cash is projected to fund operations only into the second half of 2026, leading management to raise "substantial doubt about its ability to continue as a going concern" without securing new capital or strategic transactions. This directly indicates significant financial instability and a limited funding runway.
Show more
1. Reverse Stock Split Implemented to Address Nasdaq Compliance.
Adial Pharmaceuticals executed a 1-for-25 reverse stock split effective February 5, 2026, to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. While intended to boost the per-share price, such actions often signal underlying financial difficulties and can contribute to investor apprehension regarding the company's long-term viability, leading to further stock depreciation.
2. Substantial Doubt Raised About Company's Ability to Continue as a Going Concern.
In its Q1 2026 financial results, Adial Pharmaceuticals disclosed a net loss of $2.0 million and reported cash and cash equivalents of $4.6 million as of March 31, 2026. The company explicitly stated that its existing cash is projected to fund operations only into the second half of 2026, leading management to raise "substantial doubt about its ability to continue as a going concern" without securing new capital or strategic transactions. This directly indicates significant financial instability and a limited funding runway.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -62.3% change in ADIL stock from 1/31/2026 to 5/19/2026 was primarily driven by a -35.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.33 | 2.01 | -62.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -35.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/19/2026| Return | Correlation | |
|---|---|---|
| ADIL | -61.3% | |
| Market (SPY) | 6.3% | 4.6% |
| Sector (XLV) | -4.4% | 2.5% |
Fundamental Drivers
The -77.0% change in ADIL stock from 10/31/2025 to 5/19/2026 was primarily driven by a -69.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.74 | 2.01 | -77.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -69.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/19/2026| Return | Correlation | |
|---|---|---|
| ADIL | -76.4% | |
| Market (SPY) | 8.2% | 12.7% |
| Sector (XLV) | 3.0% | 0.3% |
Fundamental Drivers
The -88.3% change in ADIL stock from 4/30/2025 to 5/19/2026 was primarily driven by a -81.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.25 | 2.01 | -88.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -81.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/19/2026| Return | Correlation | |
|---|---|---|
| ADIL | -88.1% | |
| Market (SPY) | 33.8% | 11.2% |
| Sector (XLV) | 6.7% | 3.2% |
Fundamental Drivers
The -99.1% change in ADIL stock from 4/30/2023 to 5/19/2026 was primarily driven by a -97.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5192026 | Change |
|---|---|---|---|
| Stock Price ($) | 215.31 | 2.01 | -99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -97.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/19/2026| Return | Correlation | |
|---|---|---|
| ADIL | -99.0% | |
| Market (SPY) | 83.3% | 8.0% |
| Sector (XLV) | 16.0% | 1.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ADIL Return | 59% | -92% | -65% | -46% | -78% | -71% | -100% |
| Peers Return | -5% | 104% | -0% | -16% | 61% | 13% | 195% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| ADIL Win Rate | 50% | 8% | 25% | 42% | 17% | 20% | |
| Peers Win Rate | 52% | 50% | 53% | 42% | 55% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ADIL Max Drawdown | -47% | -93% | -88% | -71% | -80% | -79% | |
| Peers Max Drawdown | -58% | -53% | -48% | -49% | -36% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALKS, INDV, ACAD, AXSM, KPRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/19/2026 (YTD)
How Low Can It Go
| Event | ADIL | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -15.1% | -7.8% |
| % Gain to Breakeven | 17.8% | 8.5% |
| Time to Breakeven | 78 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.3% | -6.7% |
| % Gain to Breakeven | 89.8% | 7.1% |
| Time to Breakeven | 1 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.8% | -33.7% |
| % Gain to Breakeven | 53.4% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -55.2% | -19.2% |
| % Gain to Breakeven | 123.1% | 23.8% |
| Time to Breakeven | 15 days | 105 days |
In The Past
Adial Pharmaceuticals's stock fell -15.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 17.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ADIL | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -47.3% | -6.7% |
| % Gain to Breakeven | 89.8% | 7.1% |
| Time to Breakeven | 1 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.8% | -33.7% |
| % Gain to Breakeven | 53.4% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -55.2% | -19.2% |
| % Gain to Breakeven | 123.1% | 23.8% |
| Time to Breakeven | 15 days | 105 days |
In The Past
Adial Pharmaceuticals's stock fell -15.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 17.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Adial Pharmaceuticals (ADIL)
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
AI Analysis | Feedback
Here are 1-3 brief analogies for Adial Pharmaceuticals (ADIL):
- Like a clinical-stage Vertex Pharmaceuticals, but focused on developing treatments for addiction rather than genetic diseases.
- A very early-stage Gilead Sciences, but specializing in addiction treatments instead of infectious diseases.
AI Analysis | Feedback
- AD04: A selective serotonin-3 antagonist currently in Phase III clinical trials for the treatment of alcohol use disorder.
- Drug candidates for non-opioid pain reduction: Therapeutics being developed to offer alternatives for pain management without using opioids.
- Drug candidates for other diseases and disorders: A broader category of therapeutics in development addressing various other medical conditions.
AI Analysis | Feedback
Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company primarily engaged in the research and development of therapeutic drug candidates. As such, the company does not currently have major commercial customers, as its lead product, AD04, is still in Phase III clinical trials and has not yet been approved for commercial sale or distribution.
AI Analysis | Feedback
- ICON plc (ICLR)
AI Analysis | Feedback
Cary J. Claiborne, Chief Executive Officer Mr. Claiborne was appointed Chief Executive Officer of Adial Pharmaceuticals in August 2022, having previously served as Chief Operating Officer from December 2021 and as a board member since November 2021. His prior experience includes serving as Chief Financial Officer and board member of Indivior PLC, where he was instrumental in leading its spin-off from Reckitt Benckiser to become an independent, publicly traded company. Mr. Claiborne also held the position of Chief Financial Officer at Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company that was subsequently sold to Mallinckrodt. Additionally, he served as Chief Financial Officer and Corporate Secretary of Osiris Therapeutics, Inc. during its initial public offering. Vinay Shah, Chief Financial Officer Mr. Shah was appointed Chief Financial Officer of Adial Pharmaceuticals, effective November 16, 2024. He brings over 20 years of finance leadership experience across the biopharmaceutical and medical device sectors. His previous roles include Chief Financial Officer at Virpax Pharmaceuticals, Inc. and Aravive, Inc. At Aravive, Mr. Shah played a key role in raising over $150 million and contributed to a significant reverse merger and out-licensing initiatives in China. He also partnered on Pacira Pharmaceuticals, Inc.'s initial public offering. Tony Goodman, Chief Operating Officer Mr. Goodman was appointed Chief Operating Officer in January 2024 and has been a member of Adial's Board of Directors since 2017. He brings extensive senior leadership and business development experience from his work with several pharmaceutical companies, including Indivior, where he collaborated closely with Cary Claiborne. Mr. Goodman held various leadership positions at Reckitt Benckiser Pharmaceuticals, including Global Director of Commercial Development and Strategic Planning, Global Head of Category Development, and Director of US Business Development and US Commercial Managed Care. Brigitte Robertson, MD, Acting Chief Medical Officer Dr. Robertson serves as the Acting Chief Medical Officer of Adial Pharmaceuticals and has nearly 20 years of academic, clinical, and pharmaceutical industry experience. She has managed global development portfolios across multiple central nervous system (CNS) indications for biotech, small, and large pharmaceutical companies. Her career began at GlaxoSmithKline as a physician scientist and she subsequently held senior clinical development roles at Sepracor/Sunovion, Neurovance, Euthymics, and Shire/Takeda, where she was Vice President and Therapeutic Area Head of Neuroscience. Dr. Robertson also served as Chief Medical Officer of Yumanity Therapeutics and, most recently, Delix Therapeutics. John R. Martin, J.D., Chief Legal Officer Mr. Martin is the Chief Legal Officer of Adial Pharmaceuticals. He is a corporate attorney with over 20 years of experience.AI Analysis | Feedback
The key risks for Adial Pharmaceuticals (ADIL) are primarily centered on its financial viability and the inherent challenges of drug development and commercialization in the biopharmaceutical industry.
- Liquidity and Going Concern Risk: Adial Pharmaceuticals faces a severe liquidity crisis, with its cash and cash equivalents projected to fund operations only into the second quarter of 2026 as of September 30, 2025. This limited cash runway is considered the single biggest threat to the company's clinical trajectory and threatens to derail the pivotal Phase 3 trial for its lead product, AD04. The company's auditor also raised substantial doubt about its ability to continue as a "going concern" in its March 2026 filing for the fiscal year ended December 31, 2025. The company requires significant financing or partnerships to proceed with its clinical programs.
- Clinical Trial and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Adial's success is heavily dependent on the successful completion of clinical trials and subsequent regulatory approval for its drug candidates, especially AD04 for Alcohol Use Disorder. Despite positive FDA feedback on the Phase 3 trial design and promising safety data from earlier studies, there is no guarantee that the Phase 3 trial will yield successful results or that regulatory approval will be granted. The company currently has no revenue, and its future growth is entirely contingent on successful clinical trials and eventual product commercialization.
- Commercialization and Market Potential Limitations: Even if AD04 receives regulatory approval, Adial Pharmaceuticals faces significant risks related to its successful commercialization. AD04 is a genetically targeted therapy, meaning it aims to treat only a subset of the Alcohol Use Disorder population identified through a specific genomic biomarker (AG+). This targeted approach, while a precision medicine strategy, inherently limits the potential market size, which could impact overall revenue and product acceptance upon launch.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Adial Pharmaceuticals (ADIL)
Alcohol Use Disorder (Main Product: AD04)
- Global Market: The global alcohol use disorder treatment market was valued at over USD 1.36 billion in 2025 and is anticipated to grow to USD 2.46 billion by 2035, at a CAGR of over 6.1% from 2026 to 2035. Other estimates suggest the global alcohol-dependency treatment market was USD 13.17 billion in 2024 and is expected to reach USD 20.05 billion by 2032. For eight major markets (United States, EU-5, Japan, and China), the revenue attained USD 6,401.3 million in 2020 and is estimated to garner USD 13,189.5 million by 2030.
- U.S. Market: The Alcohol Use Disorder market size in the United States was approximately USD 1,106 million in 2025 and is projected to increase to USD 3,489 million by 2034, growing at a CAGR of 13.6% from 2025–2034. Alcohol Use Disorder affects greater than 35 million people in the U.S. alone. North America is expected to hold a significant share of the global market, estimated at around 46% by 2035 and held the largest revenue share of 40.01% in 2024.
Non-Opioid Pain Reduction
- Global Market: The global non-opioid pain treatment market size was valued at USD 686.35 million in 2024 and is projected to reach USD 889.91 million by 2032. Other estimates are significantly higher, with the global non-opioid pain treatment market size expected to reach USD 70.30 billion by 2030, and projected to hit around USD 91.74 billion by 2033, or estimated to reach USD 96.74 billion by 2034.
- U.S. Market: The U.S. non-opioid pain treatment market generated a revenue of USD 3,057.9 million in 2024 and is expected to reach USD 4,727.4 million by 2030. Another source indicates the U.S. non-opioid pain management market was valued at USD 17.46 billion in 2024 and reached USD 18.60 billion in 2025.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Adial Pharmaceuticals (ADIL)
Over the next 2-3 years, Adial Pharmaceuticals (ADIL) is expected to have several key drivers for future revenue growth, primarily centered around the advancement and commercialization of its lead product, AD04, and its partnerships. As a clinical-stage biopharmaceutical company, its revenue growth is largely contingent on the successful progression of its pipeline through clinical trials and regulatory approvals. The primary drivers of future revenue growth for Adial Pharmaceuticals include:- U.S. Commercialization of AD04 for Alcohol Use Disorder (AUD): Adial Pharmaceuticals' lead product, AD04, a genetically targeted therapeutic for Alcohol Use Disorder (AUD), is currently in Phase III clinical trial preparations. The company has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its proposed regulatory strategy, including its 505(b)(2) bridging approach and manufacturing plans for clinical supplies. Evolving FDA policy discussions that may allow for a single pivotal trial plus confirmatory evidence could potentially lower Phase 3 costs and accelerate the timeline to a New Drug Application (NDA) submission, paving the way for eventual commercialization in the United States.
- European Commercialization of AD04 through Partnership: Adial has entered into a collaboration framework agreement with Molteni Farmaceutici for the exclusive commercialization of AD04 in Europe. This partnership is anticipated to include upfront and milestone payments, as well as tiered royalties on European net sales, with a total potential value estimated at nearly $60 million upon successful launch. This represents a significant step towards establishing a commercial pathway for AD04 outside the U.S.
- Milestone and Royalty Payments from Partnered Programs: Adial is positioned to receive milestone payments and low single-digit royalties from partnered development programs, such as with Adovate, LLC. For instance, the company has already received a six-figure milestone payment related to a Phase 1 asthma trial for a compound developed by Adovate and is eligible for substantial development, approval, and commercial milestone payments (up to $83 million for the first three compounds alone) for other partnered compounds. This provides a non-dilutive source of income as AD04 advances.
- Expansion of AD04 into Other Addictive Disorders: Beyond AUD, Adial Pharmaceuticals believes that AD04 has the potential to treat other addictive disorders, including Opioid Use Disorder, gambling, and obesity. While still in early stages for these indications, successful future development and regulatory pathways for AD04 in these expanded markets could significantly contribute to long-term revenue growth.
AI Analysis | Feedback
Share Issuance
- Adial Pharmaceuticals implemented a 1-for-25 reverse stock split effective February 5, 2026, which reduced the number of outstanding shares from approximately 27.8 million to 1.1 million. This action was primarily intended to regain compliance with Nasdaq's minimum bid price requirement.
- The company raised approximately $2.86 million in early February 2026 through a warrant inducement agreement with an existing institutional investor. This involved the exercise of Series C-1 and Series E Warrants for 9,215,675 shares of common stock.
Inbound Investments
- Adial Pharmaceuticals received a six-figure development milestone payment from Adovate, LLC in May 2025. This payment followed the commencement of a Phase 1 clinical trial evaluating Adovate's lead compound for asthma, ADO-5030.
- As of December 31, 2025, Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 2,799,643 shares, representing a 9.99% stake in Adial Pharmaceuticals.
- In March 2026, Adial entered into a collaboration framework agreement with Molteni Farmaceutici for the proposed commercialization of AD04 in Europe, with potential upfront and milestone payments, as well as royalties on European net sales, estimated to total nearly $60 million.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Adial Pharmaceuticals Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ADIL.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 28.75 |
| Mkt Cap | 4.0 |
| Rev LTM | 902 |
| Op Inc LTM | 37 |
| FCF LTM | -9 |
| FCF 3Y Avg | -5 |
| CFO LTM | -8 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 22.3% |
| Rev Chg Q | 23.7% |
| QoQ Delta Rev Chg LTM | 5.0% |
| Op Inc Chg LTM | 5.6% |
| Op Inc Chg 3Y Avg | 12.6% |
| Op Mgn LTM | 9.8% |
| Op Mgn 3Y Avg | 13.5% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 1.3% |
| CFO/Rev 3Y Avg | 1.9% |
| FCF/Rev LTM | 0.4% |
| FCF/Rev 3Y Avg | -2.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.0 |
| P/S | 3.7 |
| P/Op Inc | 6.7 |
| P/EBIT | 6.7 |
| P/E | 4.5 |
| P/CFO | -0.7 |
| Total Yield | 0.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -2.6% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.1% |
| 3M Rtn | 9.4% |
| 6M Rtn | 18.4% |
| 12M Rtn | 5.4% |
| 3Y Rtn | 7.4% |
| 1M Excs Rtn | 7.6% |
| 3M Excs Rtn | 4.7% |
| 6M Excs Rtn | 10.0% |
| 12M Excs Rtn | -18.5% |
| 3Y Excs Rtn | -66.7% |
Segment Financials
Operating Income by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug development for addiction and related disorders | -8 | ||||
| Total | -8 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug development for addiction and related disorders | -13 | ||||
| Total | -13 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Drug development for addiction and related disorders | 5 | 6 | 7 | 5 | |
| Total | 5 | 6 | 7 | 5 |
Price Behavior
Price Behavior
| Market Price | $2.06 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/27/2018 | |
| Distance from 52W High | -88.7% | |
| 50 Days | 200 Days | |
| DMA Price | $1.65 | $5.82 |
| DMA Trend | down | down |
| Distance from DMA | 24.7% | -64.6% |
| 3M | 1YR | |
| Volatility | 97.2% | 137.2% |
| Downside Capture | -69.54 | 364.17 |
| Upside Capture | -149.33 | 15.15 |
| Correlation (SPY) | 8.6% | 13.7% |
ADIL Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.33 | 0.58 | 0.78 | 1.08 | 1.44 | 0.83 |
| Up Beta | 2.00 | 1.59 | 0.66 | 0.13 | -0.89 | 0.23 |
| Down Beta | 5.17 | 4.62 | 2.76 | 1.83 | 2.32 | 1.01 |
| Up Capture | -44% | -162% | -153% | -68% | 12% | 1% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 8 | 16 | 19 | 41 | 105 | 305 |
| Down Capture | 188% | 70% | 271% | 233% | 204% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 23 | 37 | 76 | 137 | 415 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADIL | |
|---|---|---|---|---|
| ADIL | -87.6% | 137.1% | -0.95 | - |
| Sector ETF (XLV) | 12.7% | 14.7% | 0.60 | 7.0% |
| Equity (SPY) | 25.0% | 12.1% | 1.55 | 12.3% |
| Gold (GLD) | 40.0% | 26.8% | 1.23 | 2.0% |
| Commodities (DBC) | 49.4% | 18.5% | 2.03 | -3.6% |
| Real Estate (VNQ) | 9.7% | 13.4% | 0.45 | 2.9% |
| Bitcoin (BTCUSD) | -25.6% | 41.9% | -0.59 | 11.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADIL | |
|---|---|---|---|---|
| ADIL | -72.5% | 130.7% | -0.46 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 3.4% |
| Equity (SPY) | 14.2% | 17.0% | 0.65 | 9.4% |
| Gold (GLD) | 19.3% | 18.0% | 0.87 | 1.8% |
| Commodities (DBC) | 11.0% | 19.4% | 0.45 | 2.6% |
| Real Estate (VNQ) | 4.0% | 18.8% | 0.11 | 5.7% |
| Bitcoin (BTCUSD) | 9.4% | 55.6% | 0.38 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADIL | |
|---|---|---|---|---|
| ADIL | -50.9% | 141.0% | -0.09 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 6.9% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 9.6% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 1.7% |
| Commodities (DBC) | 8.4% | 17.9% | 0.38 | 5.3% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 7.2% |
| Bitcoin (BTCUSD) | 67.2% | 66.9% | 1.06 | 3.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/6/2026 | -7.1% | -5.1% | -11.2% |
| 11/14/2025 | 1.9% | -6.4% | -17.2% |
| 8/14/2025 | -1.4% | -7.0% | -12.5% |
| 5/15/2025 | 1.5% | 9.5% | -46.1% |
| 3/4/2025 | 2.6% | -1.5% | -10.3% |
| 11/14/2023 | -1.8% | 0.9% | -15.2% |
| 8/21/2023 | -1.8% | 0.6% | -24.0% |
| 3/31/2023 | -2.1% | -16.1% | -7.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 5 | 0 |
| # Negative | 6 | 6 | 11 |
| Median Positive | 2.6% | 1.1% | |
| Median Negative | -1.8% | -5.7% | -14.3% |
| Max Positive | 10.9% | 9.5% | |
| Max Negative | -7.1% | -16.1% | -46.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/04/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/21/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.